Business Wire

Dalton Maag Challenges OEM Font Status Quo with MetricsMatch

3.9.2025 08:00:00 EEST | Business Wire | Press release

Share

Dalton Maag, the independent typeface design studio known for its high-performance library fonts and custom typefaces for global brands, today launched MetricsMatch – a font solution for Original Equipment Manufacturers (OEMs). The new range provides a cost-effective, high-quality alternative to the industry-standard font sets embedded in consumer electronics, printers, and other devices.

For years, OEMs have expressed frustration with current licensing models, citing high costs, limited flexibility, and vendor lock-in. MetricsMatch directly addresses these challenges with open pricing, fair licensing, and customization options, introducing competition to the market.

At the heart of MetricsMatch is metrics compatibility, which enables the seamless substitution of fonts, reducing integration effort and accelerating time-to-market for established players and new entrants.

“We've heard the frustrations of manufacturers who feel trapped by the current licensing landscape,” said David Marshall, Managing Director of Dalton Maag. “Opaque pricing, legacy products, and restrictive terms have been holding OEMs back. We want MetricsMatch to be a better way forward for these industry-standard font sets.”

“Our studio has always been about quality and independence – and MetricsMatch is no exception,” added Lukas Paltram, Executive Creative Director at Dalton Maag. “We’ve applied the same rigour and attention to detail that we bring to every client project, ensuring that OEMs no longer have to compromise between technical performance and design integrity.”

MetricsMatch launches today with five font sets: consumer computing, PDF rendering, and DVB, MPEG-4, and ATSC closed captions and subtitles. Resident font sets for printer imaging, including 171 fonts to support PCL and PostScript emulation, are in development and scheduled for release in 2026.

Key benefits of MetricsMatch include:

  • Open Pricing: Transparent, predictable costs with no hidden fees.
  • Fair Licensing: Flexible terms that support innovation and product evolution, without renegotiation.
  • Drop-In Replacements: Dalton Maag designs adapted to industry-standard metrics, preserving line endings and layout.
  • Standards Compliance: Conformance with industry and ISO standards.
  • Exceptional Quality: World-class type design optimized for embedded devices.
  • Customization Options: Including naming rights to support product branding.

By combining meticulous design with a proven toolchain, MetricsMatch delivers high-performance font sets, empowering manufacturers with the quality, flexibility, and fairness needed to break free from supplier lock-in while creating a seamless user experience.

For more about MetricsMatch and the technologies it supports, visit daltonmaag.com/metricsmatch

About Dalton Maag

Dalton Maag is an independent typeface design studio with a global reputation for creating and engineering high-performance typefaces. With a multicultural, international team, the London-based studio designs custom and retail fonts for corporate identities, branding, and user interfaces. Its client list includes many of the world's most recognizable brands.

Trademarks

PostScript is a registered trademark of Adobe Inc. ATSC is a registered trademark of the Advanced Television Systems Committee Inc. DVB is a registered trademark of the DVB Project. PCL is a registered trademark of HP Inc. All other trademarks are the property of their respective owners.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250902922164/en/

Contacts

Media Contact

Richard Bailey
+44 3334443602
press@daltonmaag.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release

NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release

Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release

IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye